Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07177235 · ClinicalTrials.gov registry record · Phase 4
Ketamine for the Treatment of Refractory Status Epilepticus
A Phase 4 study, sponsored by Thomas Jefferson University.
- Not yet
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
NCT07177235 is a Phase 4 study that has not yet begun recruiting, run by Thomas Jefferson University. The registered enrollment target is 50 participants.
The verdict
NCT07177235, a Phase 4 study, has not yet begun recruiting, sponsored by Thomas Jefferson University.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
Study Summary
This pilot feasibility study aims to examine how the timing of ketamine introduction as a third-line anti-seizure medication infusion relates to seizure cessation in patients with refractory status epilepticus (RSE).
Interventions
- DRUG Ketamine
- DRUG Midazolam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-11 |
| Est. Completion | 2028-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07177235
The ClinicalTrials.gov registry entry for NCT07177235 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ketamine is the first listed.
NCT07177235 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07177235 about?
NCT07177235 is a clinical study titled "Ketamine for the Treatment of Refractory Status Epilepticus". This pilot feasibility study aims to examine how the timing of ketamine introduction as a third-line anti-seizure medication infusion relates to seizure cessation in patients with refractory status epilepticus (RSE).
What is the current status of trial NCT07177235?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2025-11. Estimated completion is 2028-07.
What interventions are being tested in trial NCT07177235?
The interventions under investigation include: Ketamine (DRUG), Midazolam (DRUG).
Who is sponsoring clinical trial NCT07177235?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.